CTRV vs. NCNA, UPC, HSTO, ADTX, ARDS, SCPS, VAXX, EFTR, EVLO, and CMRA
Should you be buying ContraVir Pharmaceuticals stock or one of its competitors? The main competitors of ContraVir Pharmaceuticals include NuCana (NCNA), Universe Pharmaceuticals (UPC), Histogen (HSTO), Aditxt (ADTX), Aridis Pharmaceuticals (ARDS), Scopus BioPharma (SCPS), Vaxxinity (VAXX), eFFECTOR Therapeutics (EFTR), Evelo Biosciences (EVLO), and Comera Life Sciences (CMRA). These companies are all part of the "medical" sector.
ContraVir Pharmaceuticals vs.
ContraVir Pharmaceuticals (NASDAQ:CTRV) and NuCana (NASDAQ:NCNA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, community ranking, profitability, media sentiment, earnings, risk and valuation.
In the previous week, NuCana had 2 more articles in the media than ContraVir Pharmaceuticals. MarketBeat recorded 2 mentions for NuCana and 0 mentions for ContraVir Pharmaceuticals. NuCana's average media sentiment score of 0.44 beat ContraVir Pharmaceuticals' score of 0.00 indicating that NuCana is being referred to more favorably in the news media.
NuCana received 32 more outperform votes than ContraVir Pharmaceuticals when rated by MarketBeat users. However, 74.49% of users gave ContraVir Pharmaceuticals an outperform vote while only 67.65% of users gave NuCana an outperform vote.
NuCana has a consensus price target of $25.00, suggesting a potential upside of 71,125.07%. Given NuCana's stronger consensus rating and higher probable upside, analysts plainly believe NuCana is more favorable than ContraVir Pharmaceuticals.
1.1% of ContraVir Pharmaceuticals shares are held by institutional investors. Comparatively, 44.0% of NuCana shares are held by institutional investors. 1.6% of ContraVir Pharmaceuticals shares are held by company insiders. Comparatively, 31.2% of NuCana shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
ContraVir Pharmaceuticals has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500. Comparatively, NuCana has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500.
NuCana's return on equity of -314.47% beat ContraVir Pharmaceuticals' return on equity.
Summary
NuCana beats ContraVir Pharmaceuticals on 11 of the 13 factors compared between the two stocks.
Get ContraVir Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTRV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ContraVir Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CTRV) was last updated on 5/31/2025 by MarketBeat.com Staff
Buy CTRV Stock Free CTRV Stock Alerts